Personalized Breast Cancer Treatment
131 – 140 of 148
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2015
-
Mark
Highly reproducible results of breast cancer biomarkers when analysed in accordance with national guidelines - a Swedish survey with central re-assessment.
- Contribution to journal › Article
-
Mark
Contralateral breast cancer can represent a metastatic spread of the first primary tumor: determination of clonal relationship between contralateral breast cancers using next-generation whole genome sequencing.
Alkner, Sara LU ; Tang, Man-Hung Eric LU ; Brueffer, Christian LU
; Dahlgren, Malin
LU
; Chen, Yilun
LU
; Olsson, Eleonor
LU
; Winter, Christof
LU
; Baker, Sara
LU
; Ehinger, Anna
LU
and Rydén, Lisa
LU
, et al.
(2015)
In Breast Cancer Research
17(1).
- Contribution to journal › Article
-
Mark
Prognosis, stage and oestrogen receptor status of contralateral breast cancer in relation to characteristics of the first tumour, prior endocrine treatment and radiotherapy.
Alkner, Sara LU ; Ehinger, Anna LU
; Bendahl, Pär-Ola
LU
; Rydén, Lisa
LU
and Fernö, Mårten
LU
(2015)
In European Journal of Cancer
51(16).
p.2304-2313
- Contribution to journal › Article
- 2013
-
Mark
A prospective, multicenter validation study of a prognostic index composed of S-phase fraction, progesterone receptor status, and tumour size predicts survival in node-negative breast cancer patients: NNBC, the node-negative breast cancer trial.
- Contribution to journal › Article
- 2012
-
Mark
Individually tailored treatment with epirubicin and paclitaxel with or without capecitabine as first-line chemotherapy in metastatic breast cancer: a randomized multicenter trial
- Contribution to journal › Article
- 2010
-
Mark
The prognostic value of Ki67 is dependent on estrogen receptor status and histological grade in premenopausal patients with node-negative breast cancer.
(2010) In Modern Pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 23. p.251-259
- Contribution to journal › Article
-
Mark
AIB1 is a predictive factor for tamoxifen response in premenopausal women.
Alkner, Sara LU ; Bendahl, Pär-Ola LU ; Grabau, Dorthe LU ; Lövgren, Kristina LU ; Stål, O ; Rydén, Lisa LU
and Fernö, Mårten
LU
(2010)
In Annals of Oncology
21.
p.238-244
- Contribution to journal › Article
-
Mark
Prediction of outcome after diagnosis of metachronous contralateral breast cancer
Alkner, Sara LU ; Bendahl, Pär-Ola LU ; Fernö, Mårten LU ; Manjer, Jonas LU and Ryden, Lisa LU
(2010)
San Antonio Breast Cancer Symposium 2010
In Cancer Research
70(Issue 24 suppl).
- Contribution to journal › Published meeting abstract
- 2008
-
Mark
Gene expression profiling in primary breast cancer distinguishes patients developing local recurrence after breast conservation surgery with or without postoperative radiotherapy
Niméus, Emma LU ; Krogh, Morten LU ; Malmström, Per LU ; Forsare, Carina LU
; Fredriksson, I
; Karlsson, P
; Nordenskjöld, B
; Stål, O
; Östberg, G
and Peterson, Carsten
LU
, et al.
(2008)
In Breast Cancer Research
10(2).
- Contribution to journal › Article
-
Mark
High amplified in breast cancer 1 is a significant predictor of improved response to adjuvant tamoxifen in premenopausal women
Rundquist, Sara LU ; Bendahl, Pär-Ola LU ; Grabau, Dorthe LU ; Lövgren, Kristina LU ; Stål, O ; Ryden, Lisa LU
and Fernö, Mårten
LU
(2008)
31st Annual San Antonio Breast Cancer Symposium
- Contribution to conference › Abstract